Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL INTRAVENOUS (IV) IRON DRUGS INDUSTRY
2.1 Summary about Intravenous (IV) Iron Drugs Industry
2.2 Intravenous (IV) Iron Drugs Market Trends
2.2.1 Intravenous (IV) Iron Drugs Production & Consumption Trends
2.2.2 Intravenous (IV) Iron Drugs Demand Structure Trends
2.3 Intravenous (IV) Iron Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Ferric Carboxymaltose
4.2.2 Iron Sucrose
4.2.3 Iron Dextran
4.2.4 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Nephrology
4.3.2 Gynecology & Obstetrics
4.3.3 Gastroenterology
4.3.4 Oncology
4.3.5 Cardiology
4.3.6 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Ferric Carboxymaltose
5.2.2 Iron Sucrose
5.2.3 Iron Dextran
5.2.4 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Nephrology
5.3.2 Gynecology & Obstetrics
5.3.3 Gastroenterology
5.3.4 Oncology
5.3.5 Cardiology
5.3.6 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Ferric Carboxymaltose
6.2.2 Iron Sucrose
6.2.3 Iron Dextran
6.2.4 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Nephrology
6.3.2 Gynecology & Obstetrics
6.3.3 Gastroenterology
6.3.4 Oncology
6.3.5 Cardiology
6.3.6 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Ferric Carboxymaltose
7.2.2 Iron Sucrose
7.2.3 Iron Dextran
7.2.4 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Nephrology
7.3.2 Gynecology & Obstetrics
7.3.3 Gastroenterology
7.3.4 Oncology
7.3.5 Cardiology
7.3.6 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Ferric Carboxymaltose
8.2.2 Iron Sucrose
8.2.3 Iron Dextran
8.2.4 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Nephrology
8.3.2 Gynecology & Obstetrics
8.3.3 Gastroenterology
8.3.4 Oncology
8.3.5 Cardiology
8.3.6 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Ferric Carboxymaltose
9.2.2 Iron Sucrose
9.2.3 Iron Dextran
9.2.4 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Nephrology
9.3.2 Gynecology & Obstetrics
9.3.3 Gastroenterology
9.3.4 Oncology
9.3.5 Cardiology
9.3.6 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sanofi US
10.1.2 Allergan
10.1.3 AMAG Pharmaceuticals
10.1.4 Dalichi Sankyo
10.1.5 Luitpold Pharmaceuticals
10.1.6 Pharmacosmos
10.1.7 Takeda Pharmaceutical
10.2 Intravenous (IV) Iron Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Sanofi US
10.2.2 Allergan
10.2.3 AMAG Pharmaceuticals
10.2.4 Dalichi Sankyo
10.2.5 Luitpold Pharmaceuticals
10.2.6 Pharmacosmos
10.2.7 Takeda Pharmaceutical
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Intravenous (IV) Iron Drugs Product Type Overview
Table Intravenous (IV) Iron Drugs Product Type Market Share List
Table Intravenous (IV) Iron Drugs Product Type of Major Players
Table Brief Introduction of Sanofi US
Table Brief Introduction of Allergan
Table Brief Introduction of AMAG Pharmaceuticals
Table Brief Introduction of Dalichi Sankyo
Table Brief Introduction of Luitpold Pharmaceuticals
Table Brief Introduction of Pharmacosmos
Table Brief Introduction of Takeda Pharmaceutical
Table Products & Services of Sanofi US
Table Products & Services of Allergan
Table Products & Services of AMAG Pharmaceuticals
Table Products & Services of Dalichi Sankyo
Table Products & Services of Luitpold Pharmaceuticals
Table Products & Services of Pharmacosmos
Table Products & Services of Takeda Pharmaceutical
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Intravenous (IV) Iron Drugs Market Forecast (Million USD) by Region 2021f-2026f
Table Global Intravenous (IV) Iron Drugs Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Intravenous (IV) Iron Drugs Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Intravenous (IV) Iron Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f